Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
LORMETAZEPAM
HE Clissmann
0.5 Milligram
Tablets
1982-11-01
IRISH MEDICINES BOARD ACT 1995 MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998 (S.I. NO.142 OF 1998) PA0012/051/001 Case No: 2020344 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to HE CLISSMANN T/A SCHERING 44 DARTMOUTH SQUARE, , DUBLIN 6, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product NOCTAMID TABLETS 0.5MG The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 06/03/2006 until 31/10/2007 . Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 06/03/2006_ _CRN 2020344_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Noctamid Tablets 0.5mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains lormetazepam 0.5mg For excipients, see 6.1 3 PHARMACEUTICAL FORM Tablets Round, white, flat tablets with a beveled edge, imprinted ‘CG’ in a regular hexagon on one face and a breakline on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Short-term treatment of insomnia. Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION Treatment should be as short as possible. Generally the duration of treatment varies from a few days to two weeks Pročitajte cijeli dokument